Reduction in cancer recurrences thanks to ketorolac

Christine Desmedt, researcher at the Jules Bordet Institute and U-CRC, on collaboration with the VUB, the UCL and University of Milan, published a study that suggests benefits of the inter-operative administration of an anti-inflammatory drug, ketorolac, during the ablation of a primary breast cancer tumour in overweight or obese patients. This promising results are published in the Journal of the National Cancer Institute.